Pembrolizumab in Esophageal Carcinoma: NCT07807345 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
285
Planned enrollment
2028-02-01
Primary-completion proxy
Executive view
NCT07807345 evaluates Pembrolizumab in Esophageal Carcinoma. The disclosed sponsor is Sutro Biopharma, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Part 1A, 1C: Incidence and severity of Dost-limiting Toxicities (DLTs), assessed over 21 days.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07807345 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Esophageal Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Pembrolizumab, while Company & Deal Intelligence MCP organization_fetch was queried for Sutro Biopharma, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07807345 | Pembrolizumab | Phase 1 / Not yet recruiting | Sutro Biopharma, Inc. | United States | Part 1A, 1C: Incidence and severity of Dost-limiting Toxicities (DLTs) 21 days | 2028-02-01 |
| NCT07812805 | FL-091 | Phase 1 / Recruiting | SK Life Science, Inc. | South Korea, United States | Number of Participants With Treatment-Emergent Adverse Events Following SKL35502 Administration From the first administration of SKL35502 until initiation of SKL3550… | 2030-07-01 |
| NCT07813013 | Sodium Phosphate | Not Applicable / Not yet recruiting | Westmead Hospital | Australia | Final total Boston Bowel Preparation Scale (BBPS) score on blinded external video review During colonoscopy withdrawal (single procedure) | 2028-11-01 |
| NCT07813884 | BPR001 | Not Applicable / Not yet recruiting | Centre Hospitalier Universitaire de Nice | France | Ex vivo viability of primary colorectal cancer cells after BPR001-615 exposure Day 5 of ex vivo primary cell culture, after exposure to BPR001-615. | 2027-10-01 |
| NCT07809893 | Ivonescimab | Phase 2 / Recruiting | Sun Yat-Sen University | China | Objective response rate (ORR) 3 years | 2027-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07807345 is a Phase 1, not yet recruiting study with 285 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Part 1A, 1C: Incidence and severity of Dost-limiting Toxicities (DLTs)” over “21 days.” No additional primary-endpoint description was returned in the selected field set.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 285 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
4 recent result records were selected as contextual evidence for Esophageal Carcinoma. These records do not establish direct evidence for NCT07807345 unless the registration number matches.
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer
Phase 2; n=57; ORR = 39.3 % ( 21.5 - 59.4); ORR = 35.7 % ( 18.6 - 55.9) Source: https://pubmed.ncbi.nlm.nih.gov/42421558/
Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial
Phase 3; n=1879; Lynch syndrome cancers = 75.0 Participant ; Lynch syndrome cancers = 57.0 Participant Source: https://pubmed.ncbi.nlm.nih.gov/42425127/
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Phase 2; n=71; Efficacy: The 3-month Locoregional Control Rate = 63 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT02701088
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Pembrolizumab is indexed as Monoclonal antibody with PD-1 biology and a global stage of Approved. The asset profile lists Merck & Co., Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sutro Biopharma, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Pembrolizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07807345
Protocol source: https://clinicaltrials.gov/study/NCT07807345
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Pembrolizumab in Esophageal Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Part 1A, 1C: Incidence and severity of Dost-limiting Toxicities (DLTs) and 2028-02-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
